KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exelixis (EXEL) Research & Development (2016 - 2026)

Exelixis (EXEL) has 17 years of Research & Development data on record, last reported at $213.2 million in Q1 2026.

  • For Q1 2026, Research & Development fell 14.36% year-over-year to $213.2 million; the TTM value through Jan 2026 reached $825.0 million, down 9.38%, while the annual FY2026 figure was $825.0 million, 9.38% down from the prior year.
  • Research & Development reached $213.2 million in Q1 2026 per EXEL's latest filing, up from $199.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $336.8 million in Q4 2022 and bottomed at $156.7 million in Q2 2022.
  • Average Research & Development over 5 years is $229.5 million, with a median of $217.9 million recorded in 2024.
  • Peak YoY movement for Research & Development: soared 67.27% in 2023, then crashed 33.08% in 2024.
  • A 5-year view of Research & Development shows it stood at $336.8 million in 2022, then fell by 27.36% to $244.7 million in 2023, then fell by 9.03% to $222.6 million in 2024, then dropped by 10.52% to $199.2 million in 2025, then grew by 7.07% to $213.2 million in 2026.
  • Per Business Quant database, its latest 3 readings for Research & Development were $213.2 million in Q1 2026, $199.2 million in Q4 2025, and $200.4 million in Q3 2025.